Could a nerve pain drug and exercise ease long COVID fatigue?

NCT ID NCT05967052

Terminated Symptom relief Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug pregabalin, alone or with a rehabilitation program, can reduce chronic fatigue in people with post-COVID syndrome. Participants are adults aged 18 to 65 who had COVID-19 at least six months ago and still feel very tired. The trial compares four groups: pregabalin only, rehabilitation with a placebo, rehabilitation with pregabalin, or placebo only, over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pregabalin
What this could lead to: If it works, this could point toward a treatment for chronic fatigue after COVID-19, combining medication and rehabilitation.
What could go wrong: This is a small early-phase trial, so results may not apply to everyone. Pregabalin can cause side effects like dizziness and drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC FATIGUE SYNDROME COVID-19, LONG HAUL

Contacts and locations

Locations

Centrum Wsparcia Badań Klinicznych

Warsaw, Masovian Voivodeship, 02-637, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.